Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Japanese chemical industry news
(page 3)
10 March 2026
Sekisui House Launches Japan's First Circular Window Glass Recycling Project
The project aims to recycle window glass from renovations into new glass, reducing waste, conserving resources, and lowering emissions through a closed-loop supply chain.
9 March 2026
GSK and Alfasigma License Agreement for Linerixibat Rights
Alfasigma gains global rights to develop and market linerixibat for cholestatic pruritus in PBC. GSK to receive payments and royalties. Regulatory reviews are ongoing.
9 March 2026
Chugai Recognized for Health Investment Excellence for Third Year
Chugai is acknowledged by METI and TSE for its health management initiatives, emphasizing employee well-being as key to its growth strategy and sustainable healthcare goals.
2 March 2026
Takeda's Rusfertide Receives FDA Priority Review
Rusfertide shows promise in controlling hematocrit and reducing symptoms in polycythemia vera, with FDA review based on positive Phase 3 and long-term study data.
28 February 2026
Merck and Eisai: WELIREG and LENVIMA Reduce Disease Progression Risk by 30% in Advanced RCC Trial
Phase 3 trial shows WELIREG plus LENVIMA improves progression-free survival in advanced RCC, with FDA reviewing new drug applications.
26 February 2026
GSK's Bepirovirsen Under Review in Japan for Chronic Hepatitis B Treatment
Japan reviews bepirovirsen for chronic hepatitis B. Phase III trials show higher functional cure rates and acceptable safety. SENKU designation granted for expedited review.
How does the Japanese chemical industry perform?
Find out with
chemXplore Alpha
Learn more
26 February 2026
GSK's Linerixibat Gets Priority Review in China for PBC-Related Itch
Linerixibat shows significant improvement in cholestatic pruritus in PBC patients, based on GLISTEN phase III trial data. Regulatory reviews ongoing in US, EU, UK, and Canada.
26 February 2026
TotalEnergies to Export 2 Mtpa LNG from Alaska Project for 20 Years
The Alaska LNG project, with a 20 Mtpa capacity, aims to supply Asia, enhancing energy security and transpacific ties. It has strong U.S. support and offers logistical advantages.
25 February 2026
Asahi Kasei Pharma Secures Global License with Alchemedicine for Novel Compounds
The agreement grants exclusive rights to develop preclinical compounds for autoimmune diseases, marking a deepened partnership and strategic alignment.
25 February 2026
Clariant Gains EU Approval for Rice Bran Wax in Food-Contact Plastics
EU approval allows rice bran wax additives in PET, PLA, and PVC for food-contact, offering a sustainable alternative to montan wax with lower carbon footprint and supply chain benefits.
24 February 2026
Toray Unveils Spherical PA12 Particles for Enhanced 3D Printing
New spherical PA12 particles improve 3D-printed parts' surface smoothness and impact strength, enhancing quality and expanding applications in prototypes and functional parts.
23 February 2026
Toray Develops Bio-Based Polyamide 4 for Cosmetics Market
Toray's new bio-based polyamide 4 offers biodegradability, reducing microplastic pollution in cosmetics, with potential applications in semiconductors and pharmaceuticals.
20 February 2026
Chugai Launches Japan's First Regenerative Treatment for Duchenne Muscular Dystrophy
ELEVIDYS, a one-time therapy for DMD, targets ambulatory patients aged 3-7. Safety measures and post-marketing studies are in place following reports of liver failure cases.
19 February 2026
Zenyaku's Rituxan Approved for Autoimmune Hemolytic Anemia Treatment
Rituxan gains approval for treating autoimmune hemolytic anemia, targeting B cells to reduce autoantibodies. Effective for warm AIHA, CAD, and PCH, offering an alternative to steroids.
19 February 2026
Toray's Ultrasuede™ Chosen by Case Furniture
Ultrasuede™ is used in Case's Ella Lounge and 675 Chair, enhancing sustainability and design. Toray expands its European presence with a new showroom in Portugal.
19 February 2026
Asahi Kasei Pharma Partners with MAIA for U.S. Teribone™ Development
MAIA will develop and commercialize Teribone™ in the U.S. to address the growing osteoporosis patient population, expanding access to proven bone-forming therapy.
18 February 2026
Asahi Kasei Pharma and Alchemedicine: AK1960 enters Phase I for refractory diseases
AK1960, a novel ETA receptor antagonist with a new core structure, shows high ETA selectivity and kidney-disease efficacy in animals and has advanced to Phase I for refractory diseases.
18 February 2026
Asahi Kasei Pharma Advances AK1960 to Phase I for Refractory Diseases
AK1960, an ETA receptor antagonist, enters Phase I trials for refractory diseases, leveraging Alchemedicine's HiSAP™ platform and partnerships with Calliditas and Veloxis.
18 February 2026
Toray's Ehime and Nagoya Plants Achieve ISCC PLUS Certification for Engineering Plastics
Two plants gain ISCC PLUS certification, enabling use of biomass and recycled materials in PBT and LCP resins, supporting carbon footprint reduction.
18 February 2026
Asahi Kasei Pharma Begins Phase I Study of AK1960
AK1960, a selective endothelin A receptor antagonist, shows promise for treating refractory kidney diseases, aligning with R&D strategies for unmet medical needs.
17 February 2026
Mitsubishi Chemical Transfers Synthetic Resin Emulsion Business
Mitsubishi Chemical transfers its synthetic and acrylic emulsion businesses to Konishi, aiming for sustainable growth and competitive advantage. Transfer completes December 1, 2026.
17 February 2026
Perstorp Expands Liquid Cooling Solutions for Data Centers
Perstorp introduces Synplate™ and expands Synmerse™ for efficient, safe liquid cooling in data centers, enhancing performance and sustainability.
17 February 2026
Genmab Releases 2025 Annual Report
The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
17 February 2026
Roche Appoints Mark Dawson to Executive Committee
Mark Dawson becomes Head of Pharma Research and Early Development, joining from Peter MacCallum Cancer Centre, effective May 2026.
17 February 2026
Alchemedicine and Asahi Kasei Pharma License Agreement for HiSAP Compounds
Asahi Kasei Pharma gains global rights to develop and commercialize HiSAP compounds, with Alchemedicine receiving up to ¥41.3 billion in payments and royalties.
15 February 2026
AFC Energy and Komatsu Collaborate on Ammonia-Fueled Engine Development
The JDA aims to integrate ammonia cracking tech with diesel engines, offering a sustainable solution for construction and mining equipment, with a contract value of around $2 million.
10 February 2026
ORLEN Expands LNG Operations: Increased Deliveries, Fleet, and Import Capacity
In 2025, LNG imports to Poland rose by 30%, with expanded terminal capacity and fleet. New export markets included Japan and Turkey. A second terminal will further boost capacity.
10 February 2026
FDA Grants Priority Review to Takeda's Oveporexton for Narcolepsy Type 1
Oveporexton, an orexin agonist, aims to treat narcolepsy type 1 by restoring orexin signaling. FDA's decision expected in Q3. Current treatments insufficient for many patients.
9 February 2026
MGC Participates in Japan's First Ship-to-Ship Methanol Bunkering in Yokohama
Japan completes its first ship-to-ship methanol bunkering at Yokohama, using domestically produced biomethanol, marking a key step in promoting methanol as a marine fuel.
8 February 2026
Toray Unveils PFAS-Free Flexible PPS Resin with Flame Retardancy and Heat Resistance
New PPS resin offers cost-effective, PFAS-free solution for cooling pipes and electrical parts, enhancing flexibility, flame retardancy, and heat resistance for diverse applications.
← Previous
Next →
